A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)
Active, not recruitingCTIS2024-513462-19-00
Bellus Health Inc.Including Unexplained Chronic Cough, Refractory Chronic Cough
Start: 2023-03-30Target: 257Updated: 2025-11-12